FunPep Company Limited [4881.T]
TOKYO, Jun 09 (Pulse News Wire) – FunPep Company Limited (4881.T) announced today that it has entered into a joint research agreement with artience Co., Ltd. and Toyo Chem Co., Ltd.
To develop skin absorption formulations for antibody-inducing peptides. Under the agreement, FunPep will leverage its functional peptide “AJP001” and antibody-inducing peptide drug discovery platform technology to create candidate compounds targeting various proteins. Toyo Chem, which specializes in polymer and coating technologies within the medical and healthcare sector, will focus on developing safe and skin-friendly transdermal delivery systems.
The collaboration aims to reduce invasiveness compared to injectable treatments while enhancing convenience and safety. FunPep will conduct animal efficacy and safety evaluations, while Toyo Chem will work on the formulation and absorption of the peptide through the skin. Despite the planned expenses related to their respective roles, there will be no changes to the forecasted research and development costs for the fiscal year ending December 2026.
🟢 Confidence: High AI-translated content.